You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

regorafenib (STIVARGA®)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC

Not yet recruiting
  • Stage IB Hepatocellular Carcinoma AJCC v8
  • +2 more
  • Gainesville, Florida
  • +3 more
Jun 15, 2022

Carcinoma, Hepatocellular Trial (Regorafenib in combination with nivolumab, Transarterial Chemoembolization (TACE))

Not yet recruiting
  • Carcinoma, Hepatocellular
  • Regorafenib in combination with nivolumab
  • Transarterial Chemoembolization (TACE)
  • (no location specified)
Dec 8, 2021

Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma Trial in United States

Completed
Has Results
  • Adult Angiosarcoma
  • +3 more
  • Santa Monica, California
  • +6 more
Mar 29, 2022

Glioblastoma Multiforme Trial in Italy (Regorafenib, Lomustine)

Active, not recruiting
  • Glioblastoma Multiforme
  • Castellana Grotte, BA, Italy
  • +9 more
Mar 31, 2022

Under Real-world Practice Conditions, Safety and Effectiveness

Completed
  • Liver Neoplasms
  • Regorafenib (Stivarga, BAY73-4506)
  • Gilbert, Arizona
  • +36 more
Jul 26, 2022

Bone Sarcoma, Osteosarcoma, Ewing Sarcoma Trial in France (Treatment by Regorafenib, Treatment by Placebo)

Recruiting
  • Bone Sarcoma
  • +6 more
  • Treatment by Regorafenib
  • Treatment by Placebo
  • Besançon, France
  • +15 more
Aug 18, 2022

Cancer of the Bile Duct Trial in Tampa, Chapel Hill, Richmond (Regorafenib)

Completed
Has Results
  • Cancer of the Bile Duct
  • Tampa, Florida
  • +2 more
Sep 20, 2021

KRAS Gene Mutation, Metastatic Malignant Tumor in the Brain, Recurrent Non-Small Cell Lung Carcinoma Trial in Palo Alto

Active, not recruiting
  • KRAS Gene Mutation
  • +3 more
  • Palo Alto, California
    Stanford University School of Medicine
Feb 9, 2022

Hepatocellular Carcinoma Trial in United States (Regorafenib 40 MG)

Terminated
  • Hepatocellular Carcinoma
  • Regorafenib 40 MG
  • Gilbert, Arizona
  • +8 more
Dec 10, 2021

Pancreatic Cancer Trial in United States (regorafenib)

Completed
Has Results
  • Pancreatic Cancer
  • Albemarle, North Carolina
  • +11 more
Apr 19, 2022

Hepatocellular Carcinoma, Regorafenib, PD-1 Inhibitor Trial in Beijing (Regorafenib, PD-1 inhibitor)

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Beijing, Beijing, China
    Hai-Tao Zhao
Sep 15, 2021

Adenocarcinoma of the Stomach, Adenocarcinoma of the Gastroesophageal Junction Trial in France (Regorafenib and Irinotecan,

Terminated
  • Adenocarcinoma of the Stomach
  • Adenocarcinoma of the Gastroesophageal Junction
  • Angers, France
  • +26 more
Jul 26, 2022

Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma Trial in Duarte

Active, not recruiting
  • Advanced Colon Adenocarcinoma
  • +24 more
  • Ipilimumab
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Aug 22, 2022

Gastrinoma, Glucagonoma, Insulinoma Trial in United States (regorafenib, laboratory biomarker analysis)

Completed
Has Results
  • Gastrinoma
  • +8 more
  • Scottsdale, Arizona
  • +4 more
Nov 15, 2021

Solid Tumors Trial in Worldwide (Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo))

Active, not recruiting
  • Solid Tumors
  • Regorafenib, (Stivarga, BAY73-4506)
  • Nivolumab (Opdivo)
  • Duarte, California
  • +33 more
Aug 18, 2022

Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon Trial in United States (afatinib,

Completed
  • Non-small Cell Lung Carcinoma
  • +3 more
  • Denver, Colorado
  • +7 more
Aug 17, 2022

Metastatic Solid Malignancies, Locally Advanced Solid Malignancies Trial in Edmonton (Regorafenib)

Withdrawn
  • Metastatic Solid Malignancies
  • Locally Advanced Solid Malignancies
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Jun 18, 2021

Ewing Sarcomas, Chondrosarcomas, Osteosarcomas Trial in France (Regorafenib, Placebo)

Recruiting
  • Ewing Sarcomas
  • +4 more
  • Besancon, France
  • +18 more
Apr 1, 2022

Hepatocellular Carcinoma Trial in Worldwide (Pembrolizumab, Regorafenib (Stivarga, BAY73-4506))

Active, not recruiting
  • Hepatocellular Carcinoma
  • Tucson, Arizona
  • +38 more
Aug 1, 2022

Advanced Cancer, Solid Tumor Trial in Helsinki, Kuopio, Tampere (Alectinib, Cobimetinib, Vismodegib)

Recruiting
  • Advanced Cancer
  • Solid Tumor
  • Helsinki, Uusimaa, Finland
  • +2 more
Jun 8, 2022

Colorectal Cancer; Lung Cancer Trial in Orange, Hsinchu, Taichung (TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill)

Recruiting
  • Colorectal Cancer; Lung Cancer
  • TATE and pembrolizumab
  • +2 more
  • Orange, California
  • +2 more
Apr 13, 2022

Molecular Predictors of Resistance and Response to Regorafenib

Completed
  • Metastatic Colorectal Cancer
  • Carshalton, Surrey, United Kingdom
    The Royal Marsden NHS Foundation Trust London and Surrey
Apr 30, 2021

Advanced Cancers Trial in Houston (Regorafenib, Cetuximab, Questionnaire)

Completed
  • Advanced Cancers
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Mar 31, 2021

Hepatocellular Carcinoma Trial in Hong Kong (Durvalumab, Sorafenib, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Hong Kong, Hong Kong SAR, Hong Kong
    Humanity & Health Research Centre
Mar 16, 2022

Sorafenib and/or Regorafenib in Liver Cancer Subsequent to

Terminated
  • Hepatocellular Carcinoma
  • Regorafenib (Stivarga, BAY73-4506)
  • Sorafenib (Nexavar, BAY43-9006)
  • Multiple Locations, Germany
    Many Locations
Aug 20, 2020